查詢結果分析
相關文獻
- Effect of Age on Pulmonary Metastases and Immunotherapy in Young and Middle-aged Mice
- 臺灣地區生命表之編製--蔣氏終壽年齡區間存活成數之應用
- Age and the Prognosis of Tympanoplasty Type Ⅰ
- A Population Study of House Mice (Mus Musculus Castaneus) Inhabiting Rice Granaries in Taiwan
- 國立臺灣師範大學一年級學生健康生活狀況調查與健康危險評估實驗研究
- Effect of Cigarette Smoking and Age of Disease Onset on Decline of FEV1
- 不同年齡層對基本口味嗜好性的研究
- Junior College Students' Perception and Use of Mandarin 爽(Shuang)and Taiwanese 爽(Song)--A Case Study of TJCC
- 經濟人口統計分析
- 景文技術學院男女學生應用運動場地跑走法評測心肺耐力的研究
頁籤選單縮合
題 名 | Effect of Age on Pulmonary Metastases and Immunotherapy in Young and Middle-aged Mice=年齡與免疫治療對年輕與中年小鼠肺部轉移的影響 |
---|---|
作 者 | 陳育民; 王必勝; 劉敏; 謝依霖; 蔡俊明; 彭瑞鵬; 彭汪嘉康; | 書刊名 | 中華醫學會雜誌 |
卷 期 | 70:3 2007.03[民96.03] |
頁 次 | 頁94-102+CA18 |
分類號 | 418.93 |
關鍵詞 | 年齡; 免疫治療; 肺部轉移; Age; Immunotherapy; Pulmonary metastases; |
語 文 | 英文(English) |
英文摘要 | Background: We used B16-F10 (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days’ IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice. |
本系統中英文摘要資訊取自各篇刊載內容。